Balance Sheet
Accumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CASI Pharmaceuticals (CASI) Accumulated Expenses (2022 - 2025)

Historic Accumulated Expenses for Pharmaceuticals (CASI) over the last 4 years, with Q2 2025 value amounting to $18.2 million.

  • Pharmaceuticals' Accumulated Expenses fell 9979.3% to $18.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was $18.2 million, marking a year-over-year decrease of 9979.3%. This contributed to the annual value of $15.3 million for FY2024, which is 9987.51% down from last year.
  • As of Q2 2025, Pharmaceuticals' Accumulated Expenses stood at $18.2 million, which was down 9979.3% from $14.0 billion recorded in Q1 2025.
  • Pharmaceuticals' 5-year Accumulated Expenses high stood at $14.0 billion for Q1 2025, and its period low was $8.0 million during Q1 2024.
  • Moreover, its 4-year median value for Accumulated Expenses was $4.4 billion (2024), whereas its average is $5.6 billion.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first crashed by 9987.51% in 2024, then soared by 17608389.65% in 2025.
  • Quarter analysis of 4 years shows Pharmaceuticals' Accumulated Expenses stood at $11.8 million in 2022, then soared by 103894.58% to $12.3 billion in 2023, then crashed by 99.88% to $15.3 million in 2024, then increased by 18.6% to $18.2 million in 2025.
  • Its Accumulated Expenses was $18.2 million in Q2 2025, compared to $14.0 billion in Q1 2025 and $15.3 million in Q4 2024.